Familial Haploidentical Stem Cell Transplant in Children and Adolescents with High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial

Mitchell S. Cairo; Julie An Talano; Theodore B. Moore; Qiuhu Shi; Rona Singer Weinberg; Brenda Grossman; Shalini Shenoy

doi:10.1001/jamapediatrics.2019.4715

Familial Haploidentical Stem Cell Transplant in Children and Adolescents with High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial

Mitchell S. Cairo
, Julie An Talano
, Theodore B. Moore
, Qiuhu Shi
, Rona Singer Weinberg
, Brenda Grossman
, Shalini Shenoy

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	195-197
Number of pages	3
Journal	JAMA Pediatrics
Volume	174
Issue number	2
DOIs	https://doi.org/10.1001/jamapediatrics.2019.4715
State	Published - Feb 2020

Access to Document

10.1001/jamapediatrics.2019.4715

Cite this

@article{5ef37113d944422ba5d1029133110a84,

title = "Familial Haploidentical Stem Cell Transplant in Children and Adolescents with High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial",

author = "Cairo, \{Mitchell S.\} and Talano, \{Julie An\} and Moore, \{Theodore B.\} and Qiuhu Shi and Weinberg, \{Rona Singer\} and Brenda Grossman and Shalini Shenoy",

note = "Funding Information: Funding/Support: This study was supported by FDA grant R01FD004090 (Dr Cairo) and by the PCRF, Otsuka, and Miltenyi (Dr Cairo). Miltenyi Biotec (Bergisch Gladbach, Germany) supplied the CliniMACS CD34+ reagent system. Funding Information: Conflict of Interest Disclosures: Dr Cairo reports receiving grants from the US Food and Drug Administration (FDA) (R01FD004090), the Pediatric Cancer Research Foundation (PCRF), Otsuka, and Miltenyi during the conduct of the study. No other disclosures were reported.",

year = "2020",

month = feb,

doi = "10.1001/jamapediatrics.2019.4715",

language = "English",

volume = "174",

pages = "195--197",

journal = "JAMA Pediatrics",

issn = "2168-6203",

number = "2",

}

TY - JOUR

T1 - Familial Haploidentical Stem Cell Transplant in Children and Adolescents with High-Risk Sickle Cell Disease

T2 - A Phase 2 Clinical Trial

AU - Cairo, Mitchell S.

AU - Talano, Julie An

AU - Moore, Theodore B.

AU - Shi, Qiuhu

AU - Weinberg, Rona Singer

AU - Grossman, Brenda

AU - Shenoy, Shalini

N1 - Funding Information: Funding/Support: This study was supported by FDA grant R01FD004090 (Dr Cairo) and by the PCRF, Otsuka, and Miltenyi (Dr Cairo). Miltenyi Biotec (Bergisch Gladbach, Germany) supplied the CliniMACS CD34+ reagent system. Funding Information: Conflict of Interest Disclosures: Dr Cairo reports receiving grants from the US Food and Drug Administration (FDA) (R01FD004090), the Pediatric Cancer Research Foundation (PCRF), Otsuka, and Miltenyi during the conduct of the study. No other disclosures were reported.

PY - 2020/2

Y1 - 2020/2

UR - https://www.scopus.com/pages/publications/85076336992

U2 - 10.1001/jamapediatrics.2019.4715

DO - 10.1001/jamapediatrics.2019.4715

M3 - Letter

C2 - 31816036

AN - SCOPUS:85076336992

SN - 2168-6203

VL - 174

SP - 195

EP - 197

JO - JAMA Pediatrics

JF - JAMA Pediatrics

IS - 2

ER -

Familial Haploidentical Stem Cell Transplant in Children and Adolescents with High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial

Access to Document

Other files and links

Cite this